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Conversely to normal cells, where deregulated oxidative stress drives the activation of death pathways, malignant cells exploit
oxidative milieu for its advantage. Cancer cells are located in a very complex microenvironment together with stromal components
that participate to enhance oxidative stress to promote tumor progression. Indeed, convincing experimental and clinical evidence
underline the key role of oxidative stress in several tumor aspects thus affecting several characteristics of cancer cells. Oxidants
influence the DNA mutational potential, intracellular signaling pathways controlling cell proliferation and survival and cell
motility and invasiveness as well as control the reactivity of stromal components that is fundamental for cancer development
and dissemination, inflammation, tissue repair, and de novo angiogenesis. This paper is focused on the role of oxidant species
in the acquisition of two mandatory features for aggressive neoplastic cells, recently defined by Hanahan and Weinberg as new
“hallmarks of cancer”: tumor microenvironment and metabolic reprogramming of cancer cells.
1. Introduction
With over 3 million novel cases each year in Europe, cancer is
amain public health hitch with a vital need for new therapies.
Hanahan and Weinberg defined in the 2000s the so-called
hallmarks of cancers, mandatory characteristics of virtually
all neoplastic cells, enabling them to grow in a foreign
and hostile environment and allowing escaping endogenous
protective systems [1]. These hallmarks are listed in our
reinterpretation of the Hanahan and Weinberg picture
(Figure 1). Firstly, we mention self-sufficiency in growth
signals, that is, the ability of several cancer cells to produce
in autocrine manner growth factors and cytokines, as well
as the development of compensatory mechanisms enhancing
growth factor receptor. activation [2, 3]. The insensitivity
to natural growth arrest signals, as the abolishment of
cell contact inhibition, and the ability to evade apoptosis
are two other intimately correlated cues of neoplastic cells
[2–4]. Cancer cells evade apoptotic death due to lack of
cell adhesion, a process called anoikis, as well as death
induced by several chemotherapeutic drugs, thereby leading
to chemoresistance, at present the main obstacle to fight
cancer dissemination [3–8]. Beside evasion from apoptotic
death, cancer cells also escape senescence and the limiting
in lifespan, overcoming immortalization. Last, they achieve
two further features, which strongly facilitate dissemination
of metastatic colonies and repopulation tumors elsewhere.
Indeed the ability to recruit de novo formed vessels, the so-
called neoangiogenesis or vasculogenesis, is mandatory first
to grant nutrient supply once the tumor is grown and need
new vasculature, and then to create a new way to reach
the circulation and disseminate metastases to other organs
[9]. Last, aggressive tumors increase their ability to invade
surrounding tissues by enhancing their motility and ability
to proteolytically degrade basal membrane and extracellular
matrices [10].
Our paper is built upon mounting evidence that oxida-
tive stress underlies many of the hallmarks of cancer as
defined by Hanahan and Weinberg [29]. Studies in several
cancers, including breast, prostate, and colon carcinoma,
as well as melanoma, have clearly established that oxida-
tive stress players are expressed aberrantly in cancers and
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Figure 1: ROS play multiple roles in the hallmarks of cancers. Contribution of oxidants is indicated for each point (see text for details).
(1) Self-sufficiency in proliferation signals: most normal cells wait for an external message before dividing. Conversely, cancer cells often
counterfeit their individual proliferative messages. ROS a play role in ligand-independent RTK transactivation, decreased RTK activation
threshold [11, 12]. (2) Insensitivity to antiproliferation signals: as the tumor enlarges, it squeezes adjacent tissues and therefore receives
messages that would normally stop cell division. Malignant cells ignore these command. ROS are involved in p53 activation, loss of contact
inhibition, and loss of anchorage dependence [12–14]. (3) Invasion and metastasis: cancers usually lead to death only after they overcome
their confines to the particular organ in which they arose. Cancer cells need to escape the primary tumour, invade matrix of different organs,
find a suitable metastatic niche, and then grow in this secondary site. ROS play a role in Met overexpression, matrix metalloproteinase
secretion, invadopodia formation, and plasticity in cell motility, EMT [12, 15–18]. (4) Limitless replication: healthy cells can divide no more
than 70 times, but malignant cells need more than 70 cycles to make tumours. Hence tumours need to enforce the reproductive limit of
cells. ROS are involved in expression of telomerase [12, 19]. (5) Continuous angiogenesis: tumour is characterized by a chronically activated
angiogenesis due to an unbalanced mix of pro-angiogenic signals thus sustaining cancer “feeding.” ROS play role in: endothelial progenitor
activation, signalling of VEGF and angiopoietin, recruitment of perivascular cells, release of VEGF [20–22]. (6) Escaping apoptosis: in
healthy cells, several conditions (including genetic damage or lack of ECM adhesion) activate a suicide program, but tumour cells bypass
these mechanisms, thereby surviving to death messages. ROS are involved in PTEN inactivation, Src activation, Anoikis resistance, NF-κB
activation, and CREB activation [4, 12, 23–25]. (7) Change of cell metabolism tumours have the capability to modify or reprogram cellular
metabolism to successfully carry on the neoplastic progression. ROS are involved in Warburg effect, upregulation of glucose transporter,
activation of oncogene (Ras, Myc) and mutation of tumour suppressor (p53), and increase of HIF-1 [12, 26–28]. (8) Escaping immune
destruction tumours acquire the capability to evade natural immunological destruction by T and B lymphocytes, macrophages, and natural
killer cells [29]. Furthermore, there are two additional characteristics facilitating the acquisition of aggressive features called “enabling
characteristics.” (9) Genome instability and mutation genomic alteration due to epigenetic mechanisms, the increase rate of mutation, or
enhanced sensitivity to mutagenic agents can drive tumour progression. ROS are involved in increasing the rates of mutation, increasing
sensibility to mutagenic agents, and compromising the surveillance systems [12, 29, 30]. (10) Tumor promoting inflammation innate
immune cells, which are designed to fight infections and heal wounds, inadequately support the acquisition of hallmark capabilities with
this leading to tumor expansion. ROS are involved in acquisition of mutation by neoplastic cells, thus accelerating their evolution towards
heightened malignancy [29, 31].
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positively affects mandatory steps of cancer initiation and
progression, by acting on cell proliferation and anchorage
independent cell growth, causing insensitivity to apoptosis,
sustaining de novo angiogenesis, and by altering the migra-
tion/invasion programme through metabolic and epigenetic
mechanisms (Figure 1). In this scenario, Reactive Oxygen
Species (ROS) exert a key role affecting several hallmarks of
cancer. Indeed, ROS are involved in proliferation by a ligand-
independent transactivation of receptor tyrosine kinase and
ERK activation as well as in promoting tissue invasion
and metastatic dissemination due to metalloproteinase
secretion/activation and epithelial mesenchymal transition.
In addition, ROS are involved in tumor angiogenesis,
through the release of vascular endothelial growth factor and
angiopoietin and for evading apoptosis/anoikis [3, 4, 13, 20,
32–37].
In cancer cells, high levels of ROS can result from
increased basal metabolic activity, mitochondrial dysfunc-
tion due to hypoxia or mitophagy, peroxisome activity,
uncontrolled growth factor of cytokines signaling, and
oncogene activity, as well as from enhanced activity of known
ROS sources as NADPH oxidase (NOXes), cyclooxygenases
(COXes), or lipoxygenases (LOXes) [11, 38, 39]. Compelling
experimental and clinical evidence indicates that ROS can
promote many aspects of tumour onset and progression
towards a malignant phenotype. In general, the activity of
oxidants on tumors can depends on (i) their mutagenic
potential, a mandatory factor for tumor initiation [40], (ii)
their effects on intracellular signaling pathways controlling
cell proliferation and survival [32, 33]; (iii) their impact
on cell motility and invasiveness [12, 40], and (iv) their
recognized role in stromal reactivity, mandatory for cancer
development and dissemination, like inflammation, tissue
repair, and de novo angiogenesis [40, 41].
Consequences of the production of oxygen radicals on
cancer biology are pleiotropic and complex. Currently, our
incomplete knowledge of the entire network of reactions and
effects profoundly hinders the implementation of novel and
effective redox-based anticancer strategies. In fact, besides
being directly involved in mutagenesis and genomic insta-
bility, ROS also contribute epigenetically to cancer develop-
ment and progression, by acting as signalling intermediates
downstream of mitogen receptors and adhesion molecules
and as inducers of genetic programs leading to cell invasion
and malignancy. Furthermore, oxidation of cell constituents
is a general cause of cell stress and promotes spontaneous
and therapy-induced tumor cell death by making cells more
vulnerable. Resistance to oxidative stress appears to be a
major mechanism of tumor chemo- and radioresistance.
Such diverse biological effects likely reflect distinct biochem-
ical mechanisms operating in different compartments within
cells.
Recently, both tumor microenvironment and metabolic
reprogramming have been included in the Hallmarks of
Cancer model, in a revised perspective of the old hallmarks
[29]. Both features, enabling cancer cells to achieve a more
aggressive phenotype, have been correlated to oxidative stress
and will be described below.
2. Tumor Microenvironment and
Oxidative Stress
Beside cell-autonomous process involving genetically trans-
formed cancer cells exposed to intrinsic oxidative stress,
the importance of stromal cell types populating the
tumoral microenvironment is now well established. Indeed,
tumor microenvironment may affect evolution of can-
cers towards aggressiveness and metastatic dissemination
through both structure-and function- based (matrix com-
position, hypoxia, acidity) or cell-based (cancer associated
fibroblasts (CAFs) or macrophages (CAMs), endothelial pre-
cursors, etc.) mechanisms. Several factors, such as hypoxia
or presence of CAFs or CAMs, have already been proven
to elicit a prooxidant environment deeply affecting tumor
progression and metastasis spread in several cancer models
[2, 40–42] (Figure 2).
CAFs, originated either by resident fibroblasts or by
recruitment of circulating mesenchymal stem cells [54, 55],
become activated, in response to tumor-delivered factors,
through a mesenchymal-mesenchymal transition (MMT)
converting them into “activated fibroblasts” similarly to
myofibroblasts [54, 56]. Fibroblasts activation is profoundly
affected by oxidative stress in both neoplastic and fibrotic
diseases [41, 47, 57, 58]. Oxidative stress in tumours can be
either intrinsic or extrinsic. Indeed, in skin carcinogenesis
model, TGFβ1 increases the intracellular ROS level in stro-
mal fibroblasts, which initiated the MMT and concomitant
changes of gene expression, leading to the secretion of
Hepatocyte Growth Factor, Interleukine-6, and Vascular
Endothelial Growth Factor that result in proinvasive signals
for migration of tumour cells [47]. In addition, Toullec et
al. reported a link between myofibroblasts accumulation and
the oxidative stress in different pathophysiological conditions
(JunD-deficient animals, HER-2 amplified breast adenocar-
cinoma) [41], highlighting again the importance of oxidative
stress in CAFs reactivity. Furthermore, in the diseased
prostate stroma, MMT depends by Tumor Necrosis Factor
β1-generated oxidative stress through NOX4 activation that
leads to downregulation of ROS-scavenging enzymes such
as glutathione peroxidase 3, thioredoxin reductase 1 and
the selenium transporter selenoprotein P plasma 1 [51].
Finally, senescence is another factor greatly affecting stro-
mal oxidative stress. Indeed, DNA damage accumulation
associated with ageing is involved in deregulation of ROS
generation and decrease of antioxidant defences [59]. Indeed,
senescent fibroblasts generate an inflammatory environment
through the secretion of proinflammatory cytokines and
proteases called senescence-activated secretory pathways,
SASPs [60]. SASPs comprise soluble signalling factors,
chemokines, insulin-like growth factor-1, secreted proteases,
tissue-type plasminogen activators, the uPA receptor, and the
plasminogen activator inhibitors, which concur to transform
senescent fibroblasts into proinflammatory cells that pro-
mote tumor progression [49, 50, 60].
CAMs, that concur with CAFs to promote a prooxidant
environment, have been recruited into several kinds of
tumours, where they exert their effects by different mecha-
nisms [42]. Firstly, the continuous generation of ROS, due to
4 International Journal of Cell Biology
CAMs CAFs Hypoxia Senescent fibroblasts
SASPs
ROS
Cancer cells
Tumor
progression
Intrinsic oxidative
stress:
Jun-D↓
NOX-4↑
LOX-5↑
COX-2↑
ROS
ROS ROS
O2
Figure 2: Oxidative stress in tumor microenvironment. Within microenvironment, oxidative stress can have intrinsic or extrinsic origin.
Some stromal components can directly produce ROS. CAMs generate ROS through NOX2 activation and RNS through iNOS, while hypoxia
produces oxidant species by deregulation of the complex III of mitochondrial electron transport or by NADPH oxidase activity [16, 42–46].
In response to extrinsic or intrinsic oxidative stress, CAFs became activated thus producing cytokines and proteases that affect tumour
progression [41, 47, 48]. In addition, microenvironment or ageing-induced oxidative stress leads to secretion of “Senescent Activated
Secretory Pathway” (SASP) by senescent fibroblasts affecting both stroma and cancer cells to promote cancer progression [49, 50]. Finally,
cancer cells exacerbate oxidant environment by intrinsic production of oxidative stress through down-regulation of Jun D or enhanced of
NOX-4, LOX-5 and COX-2 activity [41, 48, 51–53].
activation of macrophage NOX-2 and inducible Nitric Oxide
Synthase, could directly promote invasion and metastasis,
through CAFs recruitment or MMPs activation. Besides,
CAMs secrete proinflammatory cytokines, which coordinate
the inflammatory response in neighbouring stromal and
cancer cells, leading to cancer cells dissemination [31, 61].
A decreased oxygen pressure (hypoxia) has been reported
to be linked to an increase of intracellular/mitochondrial
ROS that synergizes with other effects due to hypoxia to
promote tumour progression [21, 43]. Mammalian cells
respond to hypoxia by activating stress signal response,
which triggers hypoxia-inducible factor (HIF-) 1 and -2 tran-
scription helpful for adaptation and survival in the hostile
milieu [62]. When cells become hypoxic, hydroxylation of
the α subunit of HIF is prevented, resulting in stabilization of
the protein and activation of its transcriptional activity. HIFα
stabilization occurs through ROS production due to electron
transport chain failure or NADPH oxidase [21, 63]. Indeed,
pharmacologic and genetic data point to ubiquinone cycle of
complex III as the source of ROS generation during hypoxia
to stabilize HIF1α protein [44, 62, 64, 65]. Intratumoral
hypoxia can produce several different effects on cancer cells,
ranging from metabolic reprogramming towards a glycolytic
phenotype, overexpression of ABC transporters, selection
of mutated cells whose apoptotic process is deficient, or
protection from apoptotic inducers. Indeed, hypoxic cancer
cells are more invasive, resistant to apoptosis and ultimately
to chemotherapy and radiation therapy [66, 67]. More-
over, mounting evidence indicates that hypoxic cancer cells
undergo exposure to oxidative stress, thereby developing
adaptive strategies to survive to the hostile milieu [12, 22].
Of note, hypoxic cells can enhance their antioxidant capacity
and hypoxia can behave as a promoting factor for this
behaviour, with a possible correlation with resistance to
therapy [11, 68].
It is important to underline that the adaptive strategies
are indeed the antioxidant responses and that an anti-oxidant
phenotype may result in increased aggressiveness.
We also recently reported that aggressive melanoma cells
respond to hypoxia engaging a motogen escaping strategy,
based on redox stabilization of HIF-1 and activation of
the Met protooncogene, allowing a proteolytic motility
enhancingmetastatic dissemination to lungs [69]. In keeping
with the key role exerted by ROS in sensing the effects of
hypoxia, Gao et al. reported that the antitumorigenic effect
of antioxidants as N-acetyl cysteine and vitamin C in murine
models of Myc-mediated tumorigenesis is indeed HIF-1-
dependent [70].
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Thus, the adaptations to surrounding stromal cells,
together with the intrinsic metabolic reprogramming of
cancer cells (see below) lead to profoundly altered ROS
production and sustained oxidative stress in tumor tissue
[32, 33]. As a consequence, oxidant-sensitive transcription
factors like Hypoxia Inducible Factor-1 (HIF-1) or Nuclear
Factor κ-B (NF-κB) become active and play a mandatory role
in eliciting a promigratory and proinflammatory response
in cancer cells [71–73]. In addition, human prostate CAFs
exert their propelling role for EMT in strict dependence
on cycloxygenase-2 (COX-2), NF-κB, and HIF-1, due to
COX-2-mediated release of reactive oxygen species, which
is mandatory for EMT, stemness, and dissemination of
metastatic cells [48, 59]. These responses, similarly elicited
by several components of tumor microenvironment, like
cancer-associated fibroblasts, hypoxia, or acidity, embrace
enhanced motility, survival to stressful environment, and
reconfiguration of metabolism. The motile response is
commonly recognised as Epithelial Mesenchymal Transition
(EMT), an epigenetic transcriptional program leading cells
to lose epithelial features and achieve mesenchymal-like
motility [74–77]. EMT has been correlated with achievement
of stem-cell like cues, as increase in the ratio of expres-
sion of CD44 and CD24, increase in CD133 expression,
and enhancement of anchorage-independent growth and
spheroid formation, as well as selection of tumor initiating
cells able to disseminate metastases [78, 79]. Again, both
EMT and stemness have been reported as redox-sensitive
and to exploit prooxidant environment to drive metastatic
dissemination and resistance to chemotherapies in several
cancer models [48, 80].
Beside the role played by stromal cells, EMT can be
also elicited by intratumoral hypoxia, acting in a bipha-
sic manner. Hypoxia-induced migration include an early
mitochondrial delivery of ROS, leading to activation of cell
polarization and oriented migration; then, there is a second
delayed phase, in which ROS act on HIF-1α stabilization
and VEGF expression, which sustains active motility [81]. In
addition, stromal elements of tumor microenvironment reg-
ulate EMT and stemness through strengthening of hypoxic
stimuli. By this way, CAFs are able to mimic the hypoxic
stimuli, experiencing HIF-1 expression due to their oxidative
stress, but without the real need for oxygen deprivation [41].
Indeed, exposure to reactive stromal fibroblasts engages an
HIF-1 and NF-κB-mediated transcriptional response driving
EMT, but that does not need hypoxia [48]. Of course it is
likely that the appearance of intratumoral hypoxia should
exacerbate this EMT programme, enhancing the motile
response (Comito, unpublished results).
Oxidative stress during ovarian tumorigenesis has been
recently correlated with a stress signature involving two
miR-200 family members, miR141 and miR200a, already
implicated in the control of EMT and stemness [82, 83]. In
particular, the paper of Mateescu et al. demonstrates that
high-grade human ovarian adenocarcinomas that accumu-
late miR-200a contain high level of ROS, which correlate
with improved survival of patients in response to treatment
and conclude that although oxidative stress promotes tumor
growth, it also sensitizes tumor to treatment, which could
account for the limited success of antioxidants in clinical
trials [84].
3. Metabolic Reconfiguration of
Tumors Undergoing Oxidative Stress
Besides and in synergy with their altered perception of the
tumor microenvironment, cancer cells undergo profound
changes in their own intrinsic metabolism. The tendency of
cancer cells to undergo Warburg metabolic reprogramming,
characterized by increased activity in aerobic glycolysis and
by lipid metabolism deregulation, is widely acknowledged.
Recently both hypoxia and CAFs have been recognised to
synergize in metabolic reprogramming of cancer cells, both
establishing a sort of “Cori cycle” between glycolytic and
respiring cells [85]. Indeed, hypoxia and/or contact with
CAFs leads cancer cells to upload lactate, produced by
neighbouring hypoxic cells or CAFs, which feeds aerobic
cancer cells through respiration and anabolic functions [86,
87].
The reconfiguration of metabolism through oxida-
tive stress occurring during cancer formation affects the
metabolic flux and network topology of pathways in central
carbon metabolism. It has been recently demonstrated
that oxidative stress leads to mitophagy and limitation of
oxidative phosphorylation [88] and to cysteine oxidation
and inactivation of the M2 isoform of pyruvate kinase,
with the consequence to enhance the level of glycolytic
intermediates that are reconverted to the pentose phosphate
cycle. This diverted pathway gives a key advantage to
cells experiencing oxidative stress, which can use NADPH
produced by pentose phosphate cycle and scavenge ROS, res-
cuing survival conditions. This adaptation was attributable
to accumulation of phosphoenolpyruvate, due to redox
inhibition of pyruvate kinase. Phosphoenolpyruvate acts as
feedback inhibitor of the glycolytic enzyme triosephosphate
isomerase, which activates the pentose phosphate pathway,
increasing antioxidative metabolism and preventing ROS
accumulation. NADPH also compensates for the oxidative
stress caused in cancer cells undergoing nucleotide/fatty acid
synthesis [89, 90]. Thesemetabolic changes have effect on the
transcriptome, allowing adaptation to cope with high ROS
level, upregulating anti-oxidant defence systems, and helping
cancer cells to reconfigure metabolic activity towards ROS
detoxification, finally enhancing the ability to survive in a
prooxidant environment.
Moreover, a crucial role in the regulation of Warburg
effect in cancer cells has been proposed for mitochondrial
SIRT3, which belongs to NAD-dependent deacetylase family,
already involved in tumour metabolism. Indeed, the genetic
loss of SIRT3 leads cancer cells to metabolic reprogramming
towards glycolysis. This shift is mediated by an increase in
cellular ROS generation that amplifies HIF-1α stabilization
and HIF-1-dependent gene expression, thereby driving the
tumor phenotype [91]. In addition, SIRT3 has been pro-
posed as tumour suppressor via its ability to suppress ROS
and regulate HIF-1α thus inhibiting tumour growth [92].
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4. Conclusions
The possibility to target cancer cell malignancy by inter-
vention on both its metabolic reprogramming and its
interplay with environmental factors is now attracting several
scientists. Effects of intratumoral hypoxia and/or infiltrating
CAFs should in principle be targeted by disrupting the
Warburg metabolism in both cancer and stromal cells, as
well as their reconfiguration towards the pentose phosphate
pathway antioxidant strategy. Promising pharmacological
approaches include drugs targeting the lactate shuttle, as
well as inhibitors of glycolysis combined with inhibitors of
autophagy, a compensatory mechanism for nutrient starved
cancer cells. Before developing such strategies, it will be
essential to deeply investigate all biochemical reactions
producing ROS within cancer cells, as well as their exact
targets and downstream effects.
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